Jacobs Levy Equity Management’s Pulmonx LUNG Stock Holding History

Jacobs Levy Equity Management’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.8K	Sell	37,081 -137,693	-79%	-$228K	﹤0.01%	949
2025 Q4	$386K	Sell	174,774 -20,004	-10%	-$37.6K	﹤0.01%	835
2025 Q3	$316K	Sell	194,778 -65,640	-25%	-$137K	﹤0.01%	875
2025 Q2	$674K	Buy	+260,418	New	+$1.03M	﹤0.01%	826
2025 Q1	–	Sell	-83,370	Closed	-$566K	–	1153
2024 Q4	$566K	Sell	83,370 -217,991	-72%	-$1.44M	﹤0.01%	798
2024 Q3	$2.5M	Sell	301,361 -188,926	-39%	-$1.37M	0.01%	564
2024 Q2	$3.11M	Buy	490,287 +292,951	+148%	+$2.25M	0.01%	524
2024 Q1	$1.83M	Sell	197,336 -167,457	-46%	-$1.96M	0.01%	612
2023 Q4	$4.65M	Sell	364,793 -140,586	-28%	-$1.46M	0.02%	438
2023 Q3	$5.22M	Sell	505,379 -175,166	-26%	-$2.03M	0.03%	372
2023 Q2	$8.92M	Buy	680,545 +27,936	+4%	+$342K	0.05%	297
2023 Q1	$7.3M	Buy	652,609 +351,526	+117%	+$3.47M	0.04%	331
2022 Q4	$2.54M	Buy	+301,083	New	+$2.86M	0.02%	509

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's LUNG Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Pulmonx (LUNG) stake by 79% in Q1 2026, selling an estimated $228K and leaving 37,081 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

Jacobs Levy Equity Management first reported a position in LUNG in Q4 2022 and has held it in 13 quarters since. The position peaked at $8.92M in Q2 2023. 113 funds tracked by Wall St. Rank hold LUNG as of Q1 2026.

Jacobs Levy Equity Management held 37,081 shares of Pulmonx worth $47.8K as of Q1 2026.
Jacobs Levy Equity Management sold 137,693 Pulmonx shares in Q1 2026, an estimated $228K.
Pulmonx made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #949 holding.
Jacobs Levy Equity Management first reported a position in Pulmonx in Q4 2022 and has held it in 13 quarters since.
Jacobs Levy Equity Management's Pulmonx position peaked at $8.92M in Q2 2023.
113 funds tracked by Wall St. Rank held Pulmonx as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.